Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of non-antibiotic antibacterial composition and application thereof

An antibacterial composition and antibiotic technology, applied in the direction of antibacterial drugs, antifungal agents, and resistance to vector-borne diseases, etc., to achieve the effect of improving broad-spectrum antibacterial properties

Active Publication Date: 2021-10-12
SUN YAT SEN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few studies on the antibacterial activity of auranofin against Gram-negative bacteria or fungi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of non-antibiotic antibacterial composition and application thereof
  • A kind of non-antibiotic antibacterial composition and application thereof
  • A kind of non-antibiotic antibacterial composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1 checkerboard method measures the inhibitory effect of auranofin and pentamidine combined medication on bacteria

[0030] 1.1 Drugs and strains

[0031] Drugs: Auranofin was purchased from Abcam Shanghai Trading Co., Ltd., and pentamidine isethionate was purchased from Dalian Meilun Biotechnology Co., Ltd.

[0032] Strains: Sensitive Escherichia coli (E.Coli), Acinetobacter baumannii (A.Baumannii 19606, A.baumannii 1789), Enterobacter aerogenes (E.Aerogenes), Staphylococcus aureus (S.Aureus), above Bacteria were purchased from ATCC; drug-resistant Escherichia coli (E.coli-1) and drug-resistant pneumoniae (K.pneumoniae-1) were donated by Professor Tian Guobao of Sun Yat-sen University School of Medicine; Candida albicans-1 , Candida albicans-2) donated by Professor Lu Sha from Sun Yat-sen Hospital.

[0033] The medicines and strains used in the present invention are obtained as described above.

[0034] 1.2 Experimental method

[0035] The bacteria descri...

Embodiment 2

[0043] Example 2 Determination of the inhibition curve of auranofin and pentamidine in combination with multidrug-resistant Acinetobacter baumannii A.baumannii 1789

[0044] Dilute auranofin (2.0, 3.9, 7.8, 15.6 μg / mL) and pentamidine (125 μg / mL) and their drug combination with MHB (pentamidine 125 μg / mL + auranofin 2.0, 3.9, 7.8, 15.6 μg / mL), the blank control group was MHB culture fluid without drugs, adding 10 5 The CFU / mL bacterial solution was cultured at 37°C and 150 rpm, and the growth of multidrug-resistant Acinetobacter baumannii 1789 at different concentrations was detected at 0-8 hours and 24 hours at an absorbance value of 600 nm.

[0045] From image 3 It can be seen that the separate administration of pentamidine and auranofin slowed down the speed of bacterial growth compared with the blank control group, but the bacterial growth was not completely inhibited. When auranofin reached a higher concentration of 15.6 μg / mL In order to basically inhibit the growth ...

Embodiment 3

[0046] Example 3 Detection of Bactericidal Kinetics of Auranofin and Pentamidine in Combination on Multidrug-resistant Acinetobacter baumannii A.baumannii 1789

[0047] Bactericidal kinetics detection of multidrug-resistant Acinetobacter baumannii-1789: MHB diluted auranofin (2.0, 15.6 μg / mL) and pentamidine (125 μg / mL) and their drug combination (pentamidine Amidine 125 μg / mL+Auranofin 2.0 μg / mL), the blank control group is the MHB culture fluid without medicine, and the concentration of adding the same volume as the medicine is 10 5 CFU / mL bacterial solution, placed in a constant temperature shaker, cultured at 37°C and 150rpm, at 0, 0.5, 1, 2, 4, 8, 24 hours, take 10 μL of the bacterial solution and dilute it to an appropriate multiple and spread it on the agar plate. Counts were made after 24 hours of incubation at 37°C.

[0048] From Figure 4 Seen in, pentamidine (125μg / mL) and auranofin (2.0μg / mL) administered alone can not inhibit bacterial growth, and its growth tre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses a non-antibiotic antibacterial composition and application thereof. In the present invention, two non-antibiotic drugs, auranofin and pentamidine, are used in combination as an antibacterial drug, which provides a new idea for the research and development of antibacterial drugs. The invention discloses that the combined use of auranofin and pentamidine can make the antibacterial properties of the medicine synergistic, which not only reduces the minimum inhibitory concentration of auranofin and pentamidine on bacteria and fungi, but also Gram-negative bacteria, fungi inhibit proliferation and disinfect the effect is very significant. In addition, the non-antibiotic antibacterial composition has inhibitory effect on various common clinical bacteria and fungi, and its broad-spectrum antibacterial activity has been improved compared with auranofin and pentamidine alone.

Description

technical field [0001] The invention relates to the technical field of antibacterial medicine, in particular to the application of a non-antibiotic antibacterial composition. Background technique [0002] In recent years, the number of multidrug-resistant bacteria found clinically is increasing, and the resistance of bacteria to various antibiotics is also increasing. Today, antibiotic resistance in bacteria has become such a serious global problem that even the antibiotic polymyxin, which is the last line of defense for multidrug-resistant Gram-negative bacteria, resistant strains have been found, and The rapid spread of drug resistance through the mechanism of plasmid transmission means that the last line of defense is about to be breached, and it also heralds the emergence of true pan-drug resistant infections. Therefore, we urgently need to develop effective new antibacterial drugs, especially antibacterial drugs against Gram-negative bacteria. However, the development...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7135A61K31/155A61P31/04A61P31/10
CPCA61K31/155A61K31/7135A61P31/04A61P31/10A61K2300/00Y02A50/30
Inventor 丁鑫余迎宵
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com